Table 4. Summary of phase II trials of chemoradiotherapy combined with gemcitabine alone or gemcitabine plus cisplatin in locally advanced pancreatic cancer.
| Study | No. of patients | Chemotherapy dose (mg m−2) | RT dose (Gy) | CR+PR (%) | Median TTP (months) | Median OS (months) | 1-year survival (%) |
|---|---|---|---|---|---|---|---|
| de Lange et al (2002) | 24 | G 300 weekly per 3 weeks | 24 | 29.2 | 7 | 10 | — |
| Li et al (2003) | 18 | G 600 weekly per 6 weeks | 50.4–61.2 | 50 | 7.1 | 14.5 | — |
| Wilkowski et al (2004) | 47 | G 300, C 30 weekly per 4 weeks | 45–50 | 68 | 7.8 | 10.7 | — |
| Okusaka et al (2004) | 42 | G 250 weekly per 6 weeks | 50.4 | 21 | 4.4 | 9.5 | 28 |
| Magnino et al (2005) | 23 | G 50, 100 biweekly per 5 weeks | 45 | 22 | — | 14 | — |
| Haddock et al (2007) | 48 | G 30, C 10 biweekly per 3 weeks | 50.4 | 8 | 7.3 | 10.2 | 40.4 |
C=cisplatin; CR=complete response; G=gemcitabine; OS=overall survival; PR=partial response; RT=radiotherapy; TTP=time to progression.